Sulfonylurea Compounds

insulin ; Homo sapiens







561 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
151 21143106 Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. 2011 Jan 2
152 21338921 Direct activation of Epac by sulfonylurea is isoform selective. 2011 Feb 25 2
153 21410858 Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. 2011 Aug 1
154 21442682 Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. 2011 Apr 1
155 21453253 Adiponectin as a regulator of vascular redox state: therapeutic implications. 2011 May 1
156 21477042 Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes. 2011 Sep 2
157 21550959 Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. 2011 Jul-Aug 1
158 21872103 Comment: "Quantitative insulin and C peptide levels among ED patients with sulfonylurea-induced hypoglycemia". 2011 Sep 1
159 21901702 Interventions for latent autoimmune diabetes (LADA) in adults. 2011 Sep 7 12
160 21959939 [Pharmacogenetics of insulin secretagogue antidiabetics]. 2011 Oct 9 2
161 22069291 Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. 2011 Nov 1
162 24843477 Genetics and pathophysiology of neonatal diabetes mellitus. 2011 Jun 5 1
163 19656320 Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation. 2010 Jun 1
164 20177722 Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. 2010 Sep 1
165 20205108 Does cellular glucose transport respond to a controlled diet and sulfonylurea therapy in type 2 diabetes mellitus? 2010 Jan-Feb 1
166 20222815 Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. 2010 Mar 1
167 20350924 Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. 2010 Jul-Aug 1
168 20361306 Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. 2010 Mar 1
169 20425680 [Diabetes, insulin, insulin analogues, and cancer]. 2010 May 3
170 20540435 [Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2]. 2010 Mar-Apr 1
171 20804735 Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. 2010 Sep 24 1
172 20887914 Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia-a prospective case series. 2010 Oct 7
173 21426008 Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription. 2010 Apr 1
174 22166651 Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone. 2010 Dec 1
175 23226049 The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes. 2010 2
176 24843406 Sulfonylurea action re-revisited. 2010 Apr 22 3
177 18548275 Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2--initial and long-term response to sulfonylurea therapy. 2009 Mar 1
178 18768334 Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents. 2009 Nov-Dec 1
179 19021632 Mutations in the ABCC8 (SUR1 subunit of the K(ATP) channel) gene are associated with a variable clinical phenotype. 2009 Sep 2
180 19050053 KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. 2009 Feb 2
181 19065048 Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. 2009 Jan 1
182 19175375 Insulin therapy in type 2 diabetes: what is the evidence? 2009 May 2
183 19275673 The endocannabinoid system: a promising target for the management of type 2 diabetes. 2009 Feb 1
184 19298459 Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. 2009 Apr 1
185 19342262 Mutations in the ABCC8 gene can cause autoantibody-negative insulin-dependent diabetes. 2009 Jun 1
186 19421967 Balancing risk and benefit with oral hypoglycemic drugs. 2009 Jun 1
187 19692134 Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride. 2009 Oct 1
188 19774848 Improved diabetic control during oral sulfonylurea treatment in two children with permanent neonatal diabetes mellitus. 2009 Jul 1
189 19885647 Cellular glucose transport and glucotransporter 4 expression as a therapeutic target: clinical and experimental studies. 2009 Nov-Dec 1
190 19950754 [Role of standard test meal in initiation of insulin therapy in type 2 diabetes]. 2009 Sep-Oct 2
191 23105828 Effects of insulin, glimepiride and combination therapy of insulin and metformin on blood sugar and lipid profile of NIDDM patients. 2009 Apr 3
192 18025408 Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. 2008 Feb 1
193 18156614 The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. 2008 Jan 1
194 18191448 Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic beta-cell. 2008 Jul 1
195 18215172 Hypoglycaemia in Type 2 diabetes. 2008 Mar 1
196 18227474 Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted? 2008 Feb 1
197 18246324 Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. 2008 Apr 1
198 18378631 Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. 2008 Apr 2 1
199 18397831 IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas. 2008 Jun 2
200 18397986 Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. 2008 Jun 2